KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods: 2018-2025

Historic Finished Goods for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Sep 2025 value amounting to $38.9 million.

  • Alnylam Pharmaceuticals' Finished Goods rose 67.99% to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year increase of 67.99%. This contributed to the annual value of $26.4 million for FY2024, which is 5.21% up from last year.
  • Alnylam Pharmaceuticals' Finished Goods amounted to $38.9 million in Q3 2025, which was up 15.11% from $33.7 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Finished Goods peaked at $38.9 million during Q3 2025, and registered a low of $7.0 million during Q4 2021.
  • For the 3-year period, Alnylam Pharmaceuticals' Finished Goods averaged around $29.0 million, with its median value being $27.9 million (2024).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Finished Goods slumped by 44.81% in 2021 and then spiked by 265.54% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Finished Goods (Quarterly) stood at $7.0 million in 2021, then spiked by 265.54% to $25.6 million in 2022, then decreased by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then spiked by 67.99% to $38.9 million in 2025.
  • Its Finished Goods was $38.9 million in Q3 2025, compared to $33.7 million in Q2 2025 and $33.0 million in Q1 2025.